Hyperhomocysteinemia and macromolecule modifications in uremic patients

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 10, 2005, Pages 1032-1038

  Perna, Alessandra F ^a   Capasso, Rosanna ^a   Lombardi, Cinzia ^a   Acanfora, Filomena ^a   Satta, Ersilia ^a   Ingrosso, Diego ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

DNA methylation; Hyperhomocysteinemia; Isopeptide bonds; Uremia

Indexed keywords

AMINO ACID; ASPARAGINE; CYSTEINE; DNA; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; ISOASPARTIC ACID; LYSINE; METHYLTRANSFERASE; S ADENOSYLHOMOCYSTEINE; THIOL GROUP;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CELL FRACTIONATION; CHRONIC KIDNEY FAILURE; CLINICAL OBSERVATION; COMPETITIVE INHIBITION; DEAMINATION; DISEASE ASSOCIATION; DNA METHYLATION; DNA MODIFICATION; ENZYME ACTIVITY; ENZYME MODIFICATION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; ISOMERIZATION; MACROMOLECULE; MOLECULAR MECHANICS; MONONUCLEAR CELL; PRECURSOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; UREMIA; VASCULAR DISEASE;

ANIMALS; DNA; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLATION; UREMIA;

EID: 27744478280     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.181     Document Type: Review

References (59)

1. Clarke S, Banfield K. S-Adenosylmethionine-dependent methyltransferases: potential targets in homocysteine-linked pathology. In: Carmel R, Jacobsen D, editors. Homocysteine in health and disease. Cambridge, UK: Cambridge University Press, 2001:63-78.
2. Clarke S, Banfield K. Can elevated plasma homocysteine levels result in the inhibition of intracellular methyltransferases? In: Milstein S, Kapatos G, Levine RA, Shane B, editors. Chemistry and biology of pteridines and folates. Boston, MA: Kluwer Academic Publishers, 2002:557-62.
3. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG. Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 1996;5:358-66.
4. Hoffer LJ. Homocysteine remethylation and transsulfuration. Metabolism 2004;53:1480-3.
5. Clarke S. A protein carboxyl methyltransferase that recognizes age-damaged peptides and proteins and participates in their repair. In: Cheng X, Blumenthal RM, editors. S-Adenosylmethionine - dependent methyltransferases: structures and function. Singapore: World Scientific Publishing Company, 1999:123-40.
6. Galletti P, Ingrosso D, Manna C, Clemente G, Zappia V. Protein damage and methylation-mediated repair in the erythrocyte. Biochem J 1995;306:313-25.
7. Clarke S. Aging as war between chemical and biochemical processes: protein methylation and the recognition of age-damaged proteins for repair. Ageing Res Rev 2003;2:263-85.
8. Barber JR, Clarke S. Inhibition of protein carboxyl methylation by S-adenosyl-L-homocysteine in intact erythrocytes. Physiological consequences. J Biol Chem 1984; 259:7115-22.
9. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D. D-Aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 1997;8:95-104.
10. Perna Al Ingrosso D, De Santo NG, Galletti P, Zappia V, Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995;47:247-53
11. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993;91:2497-503.
12. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49:31-62.
13. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
14. Malinow MR, Bostom AG, Krauss RM, Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
15. Perna AF, Acanfora F, Satta E, Lombardi C, Ingrosso D, De Santo NG. Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action. Semin Nephrol 2004; 24:426-30.
16. Jacobsen WJ. Cellular mechanisms of homocysteine pathogenesis in atherosclerosis. In: Carmel R, Jacobsen D, editors. Homocysteine in health and disease. Cambridge, UK: Cambridge University Press, 2001:425-40.
17. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004;61:470-87.
18. Jakubowski H. Homocysteine-thiolactone and S-nitrosohomocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med 2003;41: 1462-6.
19. Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:727-33.
20. Perna AF, Castaldo P, De Santo NG, Di Carlo E, Cimmino A, Galletti P, et al. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism. Kidney Int 2001,59:2299-308.
21. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001;74:723-9.
22. Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380-5.
23. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004;15:2747-54.
24. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997;8:1899-905.
25. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94: 2743-8.
26. Ghandour H, Lin BF, Choi SW, Mason JB, Selhub J. Folate status and age affect the accumulation of L-isoaspartyl residues in rat liver proteins. J Nutr 2002;132: 1357-60.
27. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ, Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-23.
28. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylene-tetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001;10:433-43.
29. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylene-tetralhydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606-11.
30. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999;9:4959-67.
31. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem 1996;271:29659-65.
32. Zhou J, Werstuck GH, Lhoták S, de Koning ABL, Sood SK, Hossain GS, et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 2004;110:207-13.
33. Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S, et al. Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH2-terminal kinase and promoter response element. Blood 2000;96:2140-48.
34. Zhang C, Kawauchi J, Adachi MT, Hashimoto Y, Oshiro S, Aso T, et al. Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. Biochem Biophys Res Commun 2001; 289:718-24.
35. Hashimoto Y, Zhang C, Kawauchi J, Imoto I, Adachi MT, Inazawa J, et al. An alternatively spliced isoform of transcriptional repressor ATF3 and its induction by stress stimuli. Nucleic Acids Res 2002;30:2398-406.
36. Nonaka H, Tsujino T, Watari Y, Emoto N, Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide disi-mutase induced by homocysteine. Amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001;104:1165-70.
37. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet 2000;1:11-9.
38. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;1:6-21.
39. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293:1068-70.
40. Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K, et al. DNA mehyltransferase contributes to delayed ischemic brain injury. J Neurosci 2000;20: 3175-81.
41. Hansen RS, Stoger R, Wijmenga C, Stanek AM, Canfield TK, Luo P, et al. Escape from gene silencing in ICF syndrome: evidence for advanced replication time as a major determinant. Hum Mol Genet 2000;9:2575-87.
42. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis M, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-9.
43. Van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999;56:1064-71.
44. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-23.
45. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, et al. Mice deficient in methylene-tetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001;10:433-43.
46. Choumenkovitch SF, Selhub J, Bagley PJ, Maeda N, Nadeau MR, Smith DE, et al. In the cystathionine betasynthase knockout mouse, elevations in total plasma homocysteine increase tissue S-adenosylhomocysteine, but responses of S-adenosylmethionine and DNA methylation are tissue specific. J Nutr 2002;132:2157-60.
47. Loehrer FM, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S-adenosylmethionine:S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998;13:656-61.
48. Laukkanen MO, Mannernnaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19:2171-8.
49. Hiltunen MO, Turunen MP, Hakkinen TP, Rutanen J, Hedman M, Makinen K, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002;7:5-11.
50. Scarano MI, Strazzullo M, Matarazzo MR, D'Esposito M. DNA methylation 40 years later: its role in human health and disease. J Cell Physiol 2005;204:21-35.
51. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003;4:235-40.
52. Yu Z, Kone BC. Hypermethylation of the inducible nitricoxide synthase gene promoter inhibits its transcription. J Biol Chem 2004;279:46954-61.
53. Sutherland JE, Costa M. Epigenetics and the environment. Ann NY Acad Sci 2003;983:151-60.
54. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA, Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 2001;10:2619-26.
55. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003;23:5293-300.
56. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet 2005;14:R139-47.
57. Devlin AM, Bottiglieri T, Domann FE, Lentz SR. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem 2005; 280:25506-11.
58. Uji Y, Motomiya Y, Hanyu N, Ukaji F, Okabe H. Proteinbound homocystamide measured in human plasma by HPLC. Clin Chem 2002;48:941-4.
59. Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo ING. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int. In press.